ライフサイエンスコーパス: upper respiratory tract infection

1 ve care unit with severe bronchospasm and an upper respiratory tract infection.

2 ty and duration of self-reported symptoms of upper respiratory tract infection.

3 chinchillas compromised by an ongoing viral upper respiratory tract infection.

4 ree of the nine relapses were preceded by an upper respiratory tract infection.

5 cription following a primary diagnosis of an upper respiratory tract infection.

6 itis media occurs as a complication of viral upper respiratory tract infection.

7 ents were pulmonary exacerbation, cough, and upper respiratory tract infection.

8 well as reduction in the incidence of viral upper respiratory tract infection.

9 of epithelial signaling in the prevention of upper respiratory tract infection.

10 Common adverse events were headache and upper respiratory tract infection.

11 were headache, cough, nasal congestion, and upper respiratory tract infection.

12 the risk of acute otitis media complicating upper respiratory tract infection.

13 growth in human saliva, an ex vivo model of upper respiratory tract infection.

14 ced prescribing of antibiotics for childhood upper respiratory tract infections.

15 ementation did not reduce overall wintertime upper respiratory tract infections.

16 operative adverse events among children with upper respiratory tract infections.

17 ion-site reactions, accidental injuries, and upper respiratory tract infections.

18 atory care are caused by uncomplicated viral upper respiratory tract infections.

19 Most sore throats are due to viral upper respiratory tract infections.

20 controlling for personal smoking and recent upper respiratory tract infections.

21 tected in aspirates from children with viral upper respiratory tract infections.

22 worldwide and represent the leading cause of upper respiratory tract infections.

23 yvitamin D levels and a higher risk of viral upper respiratory tract infections.

24 tion in children for the prevention of viral upper respiratory tract infections.

25 n of T2Rs may have therapeutic potential for upper respiratory tract infections.

26 fects humans, causing significant numbers of upper respiratory tract infections.

27 fluenza (13 [12%]), headache (11 [10%]), and upper respiratory tract infection (11 [10%]).

28 g vs nine [43%] patients receiving placebo), upper respiratory tract infection (11 [25%] patients vs

29 piratory-tract infections (3742 [55.3%]) and upper-respiratory-tract infections (1416 [20.9%]), of wh

30 t infection (19 [7%] vs 11 [4%] vs 13 [5%]), upper respiratory tract infection (15 [5%] vs 15 [5%] vs

31 both (21 [20%] of 107 vs seven [6%] of 110), upper respiratory tract infections (18 [17%] vs ten [9%]

32 hesia (22 [10%] and 11 [5%] vs 10 [5%]), and upper respiratory tract infection (20 [9%] and 23 [11%]

33 tract infection, 5.4%; otitis media, 12.2%; upper respiratory tract infection, 25.6%; bronchiolitis,

34 tmares or abnormal dreams (4 [10%] vs none), upper respiratory tract infection (3 [7%] vs none], and

35 bo and 67 [29%] for reslizumab for study 2), upper respiratory tract infections (32 [13%] and 39 [16%

36 ts with dupilumab compared with placebo were upper respiratory tract infections (33-41% vs 35%) and i

37 nasopharyngitis (30 [11%] vs 15 [11%]), and upper respiratory tract infection (35 [12%] vs ten [7%])

38 .99; P =.04 for completing participants), or upper respiratory tract infections (44% vs 52%; RR, 0.84

39 8.0%), sinusitis (4.0% and 6.3%), and viral upper respiratory tract infection (5.8% and 4.4%) for bu

40 The most common adverse events overall were upper respiratory tract infection (51 [9%] of 581 patien

41 7%] patients), rhinitis (10 [16%] patients), upper respiratory tract infection (7 [11%] patients), an

42 patients were headache (9% of the patients), upper respiratory tract infection (7%), and paresthesia

43 e events were fatigue (25%), headache (13%), upper respiratory tract infection (8%), and arthralgia (

44 brodalumab groups were nasopharyngitis (8%), upper respiratory tract infection (8%), and injection-si

45 ell children, respectively, were as follows: upper respiratory tract infection, 99% vs 97%; mild feve

46 ibiotic-inappropriate diagnoses (nonspecific upper respiratory tract infections, acute bronchitis, an

47 1) of the illness compared with infants with upper respiratory tract infection alone.

48 n used for respiratory syncytial virus (RSV) upper respiratory tract infection and lower respiratory

49 commonly reported adverse events (AEs) were upper respiratory tract infection and stomatitis of most

50 ren who present for elective surgery with an upper respiratory tract infection and suggests approache

51 At presentation, most patients (70%) had an upper respiratory tract infection and the remaining pati

52 rovirus, are responsible for the majority of upper respiratory tract infections and are associated wi

53 d in dietary supplements, primarily to treat upper respiratory tract infections and to support immune

54 of NO2 exposure in the week before or after upper respiratory-tract infection and the severity of as

55 inflammatory bowel disease, 9 subjects with upper respiratory tract infection, and 16 subjects with

56 mab, the most common were headache, abscess, upper respiratory tract infection, and fatigue.

57 common adverse events were nausea, anaemia, upper respiratory tract infection, and headache.

58 ents in any tofacitinib group were diarrhea, upper respiratory tract infection, and headache; 21 pati

59 ommonly reported adverse events were asthma, upper respiratory tract infection, and headache; 9 patie

60 ced among groups, were most commonly asthma, upper respiratory tract infection, and injection site re

61 ent adverse events were injection-site pain, upper respiratory tract infection, and nausea.

62 r respiratory tract illnesses, time to first upper respiratory tract infection, and serum 25-hydroxyv

63 mab and placebo groups were dyspnoea, cough, upper respiratory tract infection, and worsening of IPF;

64 g colds, 52% of patients diagnosed as having upper respiratory tract infections, and 66% of patients

65 iotics were for the common cold, unspecified upper respiratory tract infections, and acute bronchitis

66 ese conditions-especially colds, nonspecific upper respiratory tract infections, and acute bronchitis

67 A previous study has shown that colds, upper respiratory tract infections, and bronchitis accou

68 Office visits for colds, upper respiratory tract infections, and bronchitis resul

69 frequent antibiotic prescriptions for colds, upper respiratory tract infections, and bronchitis.

70 Infusion-related reactions, upper respiratory tract infections, and oral herpes infe

71 e antibiotic use for adults with nonspecific upper respiratory tract infections apply to immunocompet

72 who present for elective procedures with an upper respiratory tract infection are at increased risk

73 Life-threatening complications of upper respiratory tract infection are rare.

74 ntimicrobial prescribing practices for viral upper respiratory tract infections are being employed by

75 Rhinovirus (RV) upper respiratory tract infections are prototypic transi

76 te otitis media development, but symptomatic upper respiratory tract infection (as opposed to asympto

77 cted from patients with diphtheria and other upper respiratory tract infections, as well as from heal

78 activated influenza vaccine, including acute upper respiratory tract infection, asthma, bronchiolitis

79 appropriate antibiotic prescribing for acute upper respiratory tract infections (AURIs) requires a be

80 was the number of laboratory-confirmed viral upper respiratory tract infections based on parent-colle

81 15 percent of samples from 261 patients with upper respiratory tract infection but in only 1 of 86 sa

82 The most frequent respiratory disorders were upper respiratory tract infections, but the incidence of

83 be helpful in the treatment or prevention of upper respiratory tract infections, but trial data are n

84 hildren diagnosed with suspected acute viral upper respiratory tract infection by their family doctor

85 An effective vaccine against upper respiratory tract infections caused by respiratory

86 The most frequent AEs were fatigue, upper respiratory tract infection, cough, and dyspnea.

87 dache, peripheral edema, skin ulcer, anemia, upper respiratory tract infection, diarrhea, and nasopha

88 Frequently reported adverse events included upper respiratory tract infections, diarrhea, nausea and

89 ibiotic treatment of adults with nonspecific upper respiratory tract infection does not enhance illne

90 itis (eight [8%] patients in each group) and upper respiratory tract infections (five [5%] patients i

91 week 16, the most common adverse events were upper respiratory tract infections (four [4%], eight [8%

92 A week before the onset of symptoms, a mild upper respiratory tract infection had developed.

93 Subjects with asthma and those with upper respiratory tract infection had values intermediat

94 tory illnesses, such as acute bronchitis and upper respiratory tract infections, has important therap

95 Viral upper respiratory tract infections have been implicated

96 ic treatment on complications of nonspecific upper respiratory tract infections have not been perform

97 The most common AEs included arthralgia, upper respiratory tract infection, headache, fatigue, an

98 scribing rates decreased for pharyngitis and upper respiratory tract infection; however, for otitis m

99 at virulent HRV causes transient viremia and upper respiratory tract infection in addition to gastroi

100 Upper respiratory tract infection in children is one of

101 Coccidioides immitis causes a benign upper respiratory tract infection in endemic areas.

102 ea in the pitavastatin group (n=12, 10%) and upper respiratory tract infection in the pravastatin gro

103 RSV usually presents as an upper respiratory tract infection in this patient popula

104 luster-level proportion of prescriptions for upper respiratory tract infections in 2-14-year-old outp

105 mation is available on the viral etiology of upper respiratory tract infections in Cameroon.

106 lus influenzae frequently causes noninvasive upper respiratory tract infections in children but can a

107 luenzae (NTHi) frequently causes noninvasive upper respiratory tract infections in children but can c

108 diagnosis of HIES plus hypereosinophilia and upper respiratory tract infections in the absence of par

109 entation reduces the incidence of wintertime upper respiratory tract infections in young children.

110 uded mild diarrhea (in 52% of the patients), upper respiratory tract infection (in 48%), nausea (in 4

111 Common grade 1-2 toxicities included upper respiratory tract infections (in 28 [57%] of 49 pa

112 aryngitis, acute bronchitis, and nonspecific upper respiratory tract infections (including the common

113 respiratory pathogens, and the occurrence of upper respiratory tract infections, including otitis med

114 an important role in the pathogenesis of an upper respiratory tract infection induced by NTHI.

115 common adverse events were nasopharyngitis, upper respiratory tract infection, influenza, and back p

116 dministering anesthesia to the child with an upper respiratory tract infection is important in identi

117 roceed with anesthesia for the child with an upper respiratory tract infection is often difficult.

118 ea (n=29, 18%, and n=16, 10%, respectively); upper-respiratory-tract infection (n=17, 10%) and periph

119 grade 3 infections (two lung infections, one upper respiratory tract infection, one sepsis, and one m

120 The diagnosis of nonspecific upper respiratory tract infection or acute rhinopharyngi

121 ast day their child exhibited symptoms of an upper respiratory tract infection or asthma exacerbation

122 ily a childhood disease that occurs after an upper respiratory tract infection or impetigo; its occur

123 virulent human rotavirus (HRV) strains cause upper respiratory tract infections or viremia in gnotobi

124 biotics have little or no benefit for colds, upper respiratory tract infections, or bronchitis, these

125 Acute upper respiratory tract infection, otitis media, and dia

126 mporally associated with a recent history of upper respiratory tract infections (P = 0.0064), and mar

127 ctive effect of vitamin E supplementation on upper respiratory tract infections, particularly the com

128 The mean number of laboratory-confirmed upper respiratory tract infections per child was 1.05 (9

129 The most frequent adverse events were upper respiratory tract infection (placebo 6 [7%] patien

130 only observed in patients with uncomplicated upper respiratory tract infection) predict neither bacte

131 significantly worse survival than those with upper respiratory tract infection (probable: hazard rati

132 h a significant increase in the frequency of upper respiratory tract infections (r = -0.42, P < .001)

133 In this population of young children with upper respiratory tract infection, RV/EV accounted for t

134 spitalized adults varies widely and includes upper respiratory tract infections, severe lower respira

135 iously healthy individuals with a history of upper respiratory tract infection, soft tissue contusion

136 st benefit of ribavirin-based therapy at the upper respiratory tract infection stage and the highest

137 erse events in both groups were headache and upper respiratory tract infection (ten [16%] for both ev

138 principal etiologic agents of afebrile viral upper-respiratory-tract infections (the common cold).

139 nd included transient diarrhea, fatigue, and upper respiratory tract infection; thus, patients could

140 anging from 92.0% (95% CI, 89.9 to 94.1) for upper respiratory tract infections to 34.5% (95% CI, 31.

141 ts with infectious mononucleosis or ordinary upper-respiratory-tract infections until 6 months after

142 reus nasal carrier who had had an associated upper respiratory tract infection (UR) during the outbre

143 d with an increased risk of progression from upper respiratory tract infection (URI) to LRD.

144 Respiratory muscle strength during acute upper respiratory tract infection (URI) was assessed in

145 Such common diagnoses as upper respiratory tract infection, urinary tract infecti

146 apneumovirus (hMPV) plays in the etiology of upper respiratory tract infections (URIs) in children ov

147 a widely used herbal remedy for treatment of upper respiratory tract infections (URIs).

148 surement properties in acute cough caused by upper respiratory tract infection (URTI) and longitudina

149 interval (months 1-6 and month 9) and during upper respiratory tract infection (URTI) episodes.

150 the association between vitamin D status and upper respiratory tract infection (URTI) have given mixe

151 y controls, whether to exclude controls with upper respiratory tract infection (URTI) or nonsevere pn

152 DYC was completed daily from the onset of an upper respiratory tract infection (URTI) until asthma sy

153 ts were grouped according to the presence of upper respiratory tract infection (URTI) without lower r

154 Study 2 included 15 HSCT patients with RSV upper respiratory tract infection (URTI; n=3) or RSV int

155 ysicians for the common cold and nonspecific upper respiratory tract infections (URTIs) (24%), acute

156 Information on upper respiratory tract infections (URTIs) and lower res

157 xyvitamin D (25-OHD) levels and incidence of upper respiratory tract infections (URTIs).

158 ) of 246 children with suspected acute viral upper respiratory tract infection went back to see their

159 g, stroke, epilepsy, and nasal congestion or upper respiratory tract infection were also associated w

160 than either Victoria lineage and (ii) fewer upper respiratory tract infections were caused by the Vi

161 Upper respiratory tract infections were the most common

162 Twenty-eight infants had an upper respiratory tract infection where RSV was detected

163 itis media (AOM) is a common complication of upper respiratory tract infection whose pathogenesis inv

164 all expansion of CD8(+) T cells following an upper respiratory tract infection with a pathogenic infl

165 shares a receptor and a propensity to cause upper respiratory tract infections with the major group